Clinical Trials Browser

Uterine Cervical Neoplasms × Tyrosine Kinase Inhibitors × 90 days × Clear all

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms